Using the established model, it was demonstrated that simultaneous treatment with azacitidine and the MEK-inhibitor trametinib can be considered as an effective therapy in cases of NRAS-mutated CMML [101]. The gene discussed is NRAS; the disease is chronic myelomonocytic leukemia.